€ in millions 2010 2009 2008 2007 2006

Sales and Earnings

Sales 15,972 14,164 12,336 11,358 10,777

EBIT 2,418 2,054 1,727 1 1,609 1,444

Net income 2 660 1 514 1 450 1 410 330

Depreciation and amortization 639 562 783 421 399

Earnings per ordinary share in € 4.08 1 3.18 1 2.85 1 2.64 2.15 8

Earnings per preference share in € 4.08 1 3.19 1 2.86 1 2.65 2.16 8

Cash flow and Balance sheet

Operating cash flow 1,911 1,553 1,074 1,296 1,052

Operating cash flow in % of sales 12.0% 11.0% 8.7% 11.4% 9.8%

Total assets 23,577 20,882 20,544 15,324 15,024

Non-current assets 17,142 15,519 15,466 11,033 10,918

Equity 3 8,844 7,491 6,943 6,059 5,728

Net debt 8,015 7,879 8,417 5,338 5,611

Net debt / EBITDA 5, 9 2.6 3.0 3.6 2.6 3.0

Equity ratio 3 38% 36% 34% 40% 38%

Investments 4 1,402 931 4,617 1,318 4,314

Profitability

EBIT margin 15.1% 14.5% 14.0% 1 14.2% 13.4%

Return on equity after taxes (ROE) 6, 9, 10 13.3% 12.1% 10.5% 12.0% 10.4%

Return on operating assets (ROOA) 5, 9 11.6% 10.5% 9.8% 11.4% 10.4%

Return on invested capital (ROIC) 5, 9 8.9% 8.2% 7.3% 8.4% 7.4%

Dividend per ordinary share in € 0.86 7 0.75 0.70 0.66 0.57

Employees (December 31) 137,552 130,510 122,217 114,181 104,872

1 2008 before special items from the APP acquisition; 2010 and 2009 adjusted for the effects of the mark-to-market accounting of the MEB and the CVR. Both are non-cash items.

2 Net income attributable to Fresenius SE & Co. KGaA3 Equity including noncontrolling interest4 Investments in property, plant and equipment and intangible assets,

acquisitions5 2006 pro forma Renal Care Group, excluding earnings from the divestiture

of US dialysis clinics as well as their first quarter 2006 earnings

6 2006 pro forma Renal Care Group, excluding first quarter 2006 earnings of divested US dialysis clinics

7 Proposal 8 Adjusted for share split in February 2007 9 2008 pro forma APP Pharmaceuticals and excluding special items from the

APP-acquisition 10 2010 and 2009 adjusted for the effects of the mark-to-market accounting of the

MEB and the CVR

You will find a 10-year overview on our website: www.fresenius.com under “Investor Relations”.

2010 US$ in millions

2009 US$ in millions Change

2010 € in millions

2009 € in millions Change

Sales 12,053 11,247 7% 3,672 3,086 19%

EBIT 1,924 1,756 10% 737 607 21%

Net income 1 979 891 10% 294 200 47%

Operating cash flow 1,368 1,339 2% 567 397 43%

Capital expenditure / acquisitions 1,314 766 72% 205 157 31%

R & D expenses 97 94 3% 143 129 11%

Employees (December 31) 77,442 71,617 8% 22,851 21,872 4%

2010 € in millions

2009 € in millions Change

2010 € in millions

2009 € in millions Change

Sales 2,520 2,416 4% 713 618 15%

EBIT 235 205 15% 41 36 14%

Net income 1 131 107 22% 30 27 11%

Operating cash flow 311 219 42% 47 29 62%

Capital expenditure /acquisitions 179 203 - 12% 14 7 100%

Order intake n / a n / a 625 539 16%

Employees (December 31) 33,321 33,364 0% 3,110 2,849 9%

FRESENIUS MEDICAL CARE

FRESENIUS HELIOS

FRESENIUS KABI

FRESENIUS VAMED

DIALYSIS PRODUCTS,

DIALYSIS CARE

HOSPITAL OPERATION

INFUSION THERAPY, IV DRUGS,

CLINICAL NUTRITION,

MEDICAL DEVICES /

TRANSFUSION TECHNOLOGY

ENGINEERING AND SERVICES

FOR HOSPITALS AND

OTHER HEALTH CARE FACILITIES

1  Net income attributable to the parent company of the respective business segment

Key

figu

res

of t

he b

usin

ess

segm

ents

<

FRESENIUS GROUP IN FIGURES

Fres

eniu

s w

orld

wid

e >

Fresenius Headquarters

Fresenius Medical Care

Fresenius Kabi

Fresenius Helios

Fresenius Vamed

FRESENIUS WORLDWIDE

Major companies and

production plants of the

Fresenius Group.

The figures refer to fiscal

year 2010.

Sales: € 3,672 million Employees: 22,851

Fresenius HemoCare GmbHBad Homburg v. d. H., Germany Fresenius Kabi Deutschland GmbHBad Homburg v. d. H., GermanyFresenius Vial S.A.S.Brézins, FranceFresenius Kabi France S.A.S.Sèvres, FranceFresenius Kabi Italia S.p.A.Verona, ItalyFresenius Kabi Anti-Infectives S.r.l.Cernusco sul Naviglio, ItalyFresenius Kabi Ltd.Runcorn / Cheshire, Great BritainFresenius Kabi Nederland B.V.’s-Hertogenbosch, NetherlandsFresenius HemoCare Netherlands B.V.Emmen, NetherlandsFresenius Kabi N.V.Schelle, BelgiumFresenius Kabi (Schweiz) AGStans, SwitzerlandFresenius Kabi Austria GmbHGraz, Austria

Fresenius Kabi España S.A.Barcelona, SpainLabesfal - Laboratórios Almiro, S.A.Campo de Besteiros, PortugalFresenius Kabi Polska Sp. z o.o.Warsaw, PolandFresenius Kabi ABStockholm, SwedenFresenius Kabi Norge A / SHalden, NorwayFresenius Kabi Pharmaceuticals Holding, Inc. Wilmington / Delaware, USACalea Ltd. Toronto / Ontario, CanadaFresenius Kabi Brasil Ltda.São Paulo, BrazilFresenius Hemocare Brasil Ltda.São Paulo, BrazilLaboratorio Sanderson S.A.Santiago de Chile, ChileFresenius Kabi México S.A. de C.V.Guadalajara, Mexico

Sales: US$ 12,053 millionEmployees: 77,442

Further information on the companies and production plants of Fresenius Medical Care AG & Co. KGaA can be found in the company’s annual report.

Beijing Fresenius Kabi Pharmaceutical Co., Ltd. Beijing, ChinaSino-Swed Pharmaceutical Corp. Ltd. Wuxi, ChinaFresenius Kabi Oncology Ltd.New Delhi, IndiaFresenius Kabi Korea Ltd.Seoul, KoreaFresenius Kabi Australia Pty Ltd.Sydney, AustraliaFresenius Kabi South Africa (Pty) Ltd.Midrand, South Africa

FRESENIUS KABIFRESENIUS MEDICAL CARE

Sales: € 2,520 million Employees: 33,321

The HELIOS Group owns63 clinics, thereof maximum care clinics in:Berlin, GermanyErfurt, GermanyKrefeld, GermanySchwerin, GermanyWuppertal, Germany

FRESENIUS HELIOS

Sales: € 713 million Employees: 3,110

VAMED Group hascompanies / subsidiaries in:Vienna, AustriaBerlin, GermanyMadrid, SpainLisbon, PortugalArnheim, NetherlandsPrague, Czech RepublicNovi Sad, SerbiaTuzla, Bosnia-HerzegovinaBucharest, RomaniaMoscow, RussiaKiev, Donetsk, UkraineAstana, KazakhstanAshgabat, TurkmenistanBaku, AserbaijanAnkara, TurkeyBuenos Aires, ArgentinaBeijing, ChinaKuala Lumpur, MalaysiaBangkok, ThailandHanoi, VietnamJakarta, IndonesiaManila, PhilippinesAbuja, NigeriaLibreville, GabonTripoli, LibyaAbu Dhabi, UAE

FRESENIUS VAMED

€ in millions 2010 2009 2008 2007 2006

Sales and Earnings

Sales 15,972 14,164 12,336 11,358 10,777

EBIT 2,418 2,054 1,727 1 1,609 1,444

Net income 2 660 1 514 1 450 1 410 330

Depreciation and amortization 639 562 783 421 399

Earnings per ordinary share in € 4.08 1 3.18 1 2.85 1 2.64 2.15 8

Earnings per preference share in € 4.08 1 3.19 1 2.86 1 2.65 2.16 8

Cash flow and Balance sheet

Operating cash flow 1,911 1,553 1,074 1,296 1,052

Operating cash flow in % of sales 12.0% 11.0% 8.7% 11.4% 9.8%

Total assets 23,577 20,882 20,544 15,324 15,024

Non-current assets 17,142 15,519 15,466 11,033 10,918

Equity 3 8,844 7,491 6,943 6,059 5,728

Net debt 8,015 7,879 8,417 5,338 5,611

Net debt / EBITDA 5, 9 2.6 3.0 3.6 2.6 3.0

Equity ratio 3 38% 36% 34% 40% 38%

Investments 4 1,402 931 4,617 1,318 4,314

Profitability

EBIT margin 15.1% 14.5% 14.0% 1 14.2% 13.4%

Return on equity after taxes (ROE) 6, 9, 10 13.3% 12.1% 10.5% 12.0% 10.4%

Return on operating assets (ROOA) 5, 9 11.6% 10.5% 9.8% 11.4% 10.4%

Return on invested capital (ROIC) 5, 9 8.9% 8.2% 7.3% 8.4% 7.4%

Dividend per ordinary share in € 0.86 7 0.75 0.70 0.66 0.57

Employees (December 31) 137,552 130,510 122,217 114,181 104,872

1 2008 before special items from the APP acquisition; 2010 and 2009 adjusted for the effects of the mark-to-market accounting of the MEB and the CVR. Both are non-cash items.

2 Net income attributable to Fresenius SE & Co. KGaA3 Equity including noncontrolling interest4 Investments in property, plant and equipment and intangible assets,

acquisitions5 2006 pro forma Renal Care Group, excluding earnings from the divestiture

of US dialysis clinics as well as their first quarter 2006 earnings

6 2006 pro forma Renal Care Group, excluding first quarter 2006 earnings of divested US dialysis clinics

7 Proposal 8 Adjusted for share split in February 2007 9 2008 pro forma APP Pharmaceuticals and excluding special items from the

APP-acquisition 10 2010 and 2009 adjusted for the effects of the mark-to-market accounting of the

MEB and the CVR

You will find a 10-year overview on our website: www.fresenius.com under “Investor Relations”.

2010 US$ in millions

2009 US$ in millions Change

2010 € in millions

2009 € in millions Change

Sales 12,053 11,247 7% 3,672 3,086 19%

EBIT 1,924 1,756 10% 737 607 21%

Net income 1 979 891 10% 294 200 47%

Operating cash flow 1,368 1,339 2% 567 397 43%

Capital expenditure / acquisitions 1,314 766 72% 205 157 31%

R & D expenses 97 94 3% 143 129 11%

Employees (December 31) 77,442 71,617 8% 22,851 21,872 4%

2010 € in millions

2009 € in millions Change

2010 € in millions

2009 € in millions Change

Sales 2,520 2,416 4% 713 618 15%

EBIT 235 205 15% 41 36 14%

Net income 1 131 107 22% 30 27 11%

Operating cash flow 311 219 42% 47 29 62%

Capital expenditure /acquisitions 179 203 - 12% 14 7 100%

Order intake n / a n / a 625 539 16%

Employees (December 31) 33,321 33,364 0% 3,110 2,849 9%

FRESENIUS MEDICAL CARE

FRESENIUS HELIOS

FRESENIUS KABI

FRESENIUS VAMED

DIALYSIS PRODUCTS,

DIALYSIS CARE

HOSPITAL OPERATION

INFUSION THERAPY, IV DRUGS,

CLINICAL NUTRITION,

MEDICAL DEVICES /

TRANSFUSION TECHNOLOGY

ENGINEERING AND SERVICES

FOR HOSPITALS AND

OTHER HEALTH CARE FACILITIES

1  Net income attributable to the parent company of the respective business segment

Key

figu

res

of t

he b

usin

ess

segm

ents

<

FRESENIUS GROUP IN FIGURES

Fres

eniu

s w

orld

wid

e >

Fresenius Headquarters

Fresenius Medical Care

Fresenius Kabi

Fresenius Helios

Fresenius Vamed

FRESENIUS WORLDWIDE

Major companies and

production plants of the

Fresenius Group.

The figures refer to fiscal

year 2010.

Sales: € 3,672 million Employees: 22,851

Fresenius HemoCare GmbHBad Homburg v. d. H., Germany Fresenius Kabi Deutschland GmbHBad Homburg v. d. H., GermanyFresenius Vial S.A.S.Brézins, FranceFresenius Kabi France S.A.S.Sèvres, FranceFresenius Kabi Italia S.p.A.Verona, ItalyFresenius Kabi Anti-Infectives S.r.l.Cernusco sul Naviglio, ItalyFresenius Kabi Ltd.Runcorn / Cheshire, Great BritainFresenius Kabi Nederland B.V.’s-Hertogenbosch, NetherlandsFresenius HemoCare Netherlands B.V.Emmen, NetherlandsFresenius Kabi N.V.Schelle, BelgiumFresenius Kabi (Schweiz) AGStans, SwitzerlandFresenius Kabi Austria GmbHGraz, Austria

Fresenius Kabi España S.A.Barcelona, SpainLabesfal - Laboratórios Almiro, S.A.Campo de Besteiros, PortugalFresenius Kabi Polska Sp. z o.o.Warsaw, PolandFresenius Kabi ABStockholm, SwedenFresenius Kabi Norge A / SHalden, NorwayFresenius Kabi Pharmaceuticals Holding, Inc. Wilmington / Delaware, USACalea Ltd. Toronto / Ontario, CanadaFresenius Kabi Brasil Ltda.São Paulo, BrazilFresenius Hemocare Brasil Ltda.São Paulo, BrazilLaboratorio Sanderson S.A.Santiago de Chile, ChileFresenius Kabi México S.A. de C.V.Guadalajara, Mexico

Sales: US$ 12,053 millionEmployees: 77,442

Further information on the companies and production plants of Fresenius Medical Care AG & Co. KGaA can be found in the company’s annual report.

Beijing Fresenius Kabi Pharmaceutical Co., Ltd. Beijing, ChinaSino-Swed Pharmaceutical Corp. Ltd. Wuxi, ChinaFresenius Kabi Oncology Ltd.New Delhi, IndiaFresenius Kabi Korea Ltd.Seoul, KoreaFresenius Kabi Australia Pty Ltd.Sydney, AustraliaFresenius Kabi South Africa (Pty) Ltd.Midrand, South Africa

FRESENIUS KABIFRESENIUS MEDICAL CARE

Sales: € 2,520 million Employees: 33,321

The HELIOS Group owns63 clinics, thereof maximum care clinics in:Berlin, GermanyErfurt, GermanyKrefeld, GermanySchwerin, GermanyWuppertal, Germany

FRESENIUS HELIOS

Sales: € 713 million Employees: 3,110

VAMED Group hascompanies / subsidiaries in:Vienna, AustriaBerlin, GermanyMadrid, SpainLisbon, PortugalArnheim, NetherlandsPrague, Czech RepublicNovi Sad, SerbiaTuzla, Bosnia-HerzegovinaBucharest, RomaniaMoscow, RussiaKiev, Donetsk, UkraineAstana, KazakhstanAshgabat, TurkmenistanBaku, AserbaijanAnkara, TurkeyBuenos Aires, ArgentinaBeijing, ChinaKuala Lumpur, MalaysiaBangkok, ThailandHanoi, VietnamJakarta, IndonesiaManila, PhilippinesAbuja, NigeriaLibreville, GabonTripoli, LibyaAbu Dhabi, UAE

FRESENIUS VAMED